default author photo

Ian Davis

Monash University

23 Innovation Walk

Wellington Road

Clayton, 3800

Australia

  • Monash University

SCHOLARLY PAPERS

3

DOWNLOADS

141

TOTAL CITATIONS

0

Scholarly Papers (3)

Actions:
Email selected abstracts
1.

Challenges of Estimating Treatment Effects after a Positive Interim Analysis

Number of pages: 17 Posted: 06 May 2024
Yu Yang Soon, Ian C. Marschner, Manjula Schou, Christopher Sweeney, Ian Davis, Martin R. Stockler and Andrew J. Martin
The University of Sydney, The University of Sydney, The University of Sydney, University of Adelaide, Monash University, The University of Sydney - NHMRC Clinical Trials Centre and University of Queensland
Downloads 63 (933,592)

Abstract:

Loading...

Interim analysis, randomized clinical trials, overestimation bias, non-proportional hazards

2.

Pembrolizumab and Denosumab in clear-cell renal-cell carcinoma

Number of pages: 28 Posted: 15 Dec 2025
Carole A. Harris, Danka S. Zebic, Michelle F. Morrison, Tom Ferguson, Jeffrey C. Goh, Andrew J. Martin, Craig Underhill, David Pook, Laurence Krieger, Ganessan Kichenadasse, Abhishek J. Joshi, Shalini Subramaniam, Alison Zhang, Anthony Joshua, Guy C. Toner, Paul A. Vasey, Prashanth Prithviraj, Martin R. Stockler, Ian Davis and Craig Gedye
affiliation not provided to SSRN, The University of Sydney - NHMRC Clinical Trials Centre, affiliation not provided to SSRN, The University of Western Australia - Fiona Stanley Hospital, affiliation not provided to SSRN, University of Queensland, Border Medical Oncology, Monash Health, affiliation not provided to SSRN, Flinders University, affiliation not provided to SSRN, The University of Sydney - NHMRC Clinical Trials Centre, Macquarie University, The Kinghorn Cancer Centre, Peter MacCallum Cancer Centre, affiliation not provided to SSRN, affiliation not provided to SSRN, The University of Sydney - NHMRC Clinical Trials Centre, Monash University and affiliation not provided to SSRN
Downloads 43 (1,145,425)

Abstract:

Loading...

renal cell carcinoma, Immune checkpoint inhibitors, RANKL inhibition, clinical trial, pembrolizumab, denosumab

3.

Investigating the Difference in the Effects of [177lu] Lu-Psma-617 on Overall Survival between Therap and Vision Randomized Trials

Number of pages: 17 Posted: 04 Apr 2024
Yu Yang Soon, Ian C. Marschner, Manjula Schou, Prof Michael S. Hofman, Louise Emmett, Ian Davis, Martin R. Stockler and Andrew J. Martin
The University of Sydney, The University of Sydney, The University of Sydney, Peter MacCallum Cancer Centre, Royal North Shore Hospital, Monash University, The University of Sydney - NHMRC Clinical Trials Centre and University of Queensland
Downloads 35 (1,249,711)

Abstract:

Loading...

prostate cancer, Lutetium PSMA, Cabazitaxel, Survival, Treatment Crossover